Serum lipoprotein profile under different antihypertensive therapy.

Area of Science:

• Cardiology
• Pharmacology
• Biochemistry

Background:

• Essential hypertension is a common condition requiring effective treatment.
• Serum lipid profiles are crucial indicators of cardiovascular risk.
• Antihypertensive medications can influence lipid metabolism.

Purpose of the Study:

• To compare the effects of four antihypertensive therapies on serum lipid parameters.
• To evaluate changes in high-density lipoprotein cholesterol (HDL-C) and the total cholesterol/HDL-C ratio.
• To assess the impact on the atherogenic ratio in patients with essential hypertension.

Main Methods:

• 80 patients with essential hypertension received enalapril, benazepril, Epitens, or isradipine for eight weeks.
• A control group of 10 hypertensive patients received a placebo.
• Serum lipid parameters, including HDL-C and the total cholesterol/HDL-C ratio, were measured post-therapy.

Main Results:

• Enalapril significantly increased HDL-C and decreased the total cholesterol/HDL-C ratio.
• Benazepril significantly decreased the total cholesterol/HDL-C ratio.
• Both enalapril and benazepril significantly improved the atherogenic ratio; isradipine showed a lesser improvement, while Epitens caused insignificant deterioration.

Conclusions:

• Angiotensin-converting enzyme inhibitors (enalapril, benazepril) demonstrate favorable effects on lipid profiles and the atherogenic ratio in hypertensive patients.
• Calcium channel blockers (isradipine) also show some benefit, though less pronounced.
• Diuretic combination therapy (Epitens) had minimal impact on electrolytes and a negative effect on the atherogenic ratio.